View ValuationUmicore 향후 성장Future 기준 점검 1/6Umicore 의 수익은 연간 40.4% 감소할 것으로 예상되는 반면, 연간 수익은 4.4% 로 증가할 것으로 예상됩니다. EPS는 연간 3.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.1% 로 예상됩니다.핵심 정보4.4%이익 성장률3.47%EPS 성장률Chemicals 이익 성장42.1%매출 성장률-40.4%향후 자기자본이익률14.14%애널리스트 커버리지Good마지막 업데이트06 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • May 06Umicore Announces Supervisory Board AppointmentsUmicore at its ordinary and extraordinary shareholders’ meeting held on April 30th 2026 approved the appointment of Anna Bertona and Benjamin Loh as new Supervisory Board members for a term of 3 years.Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €19.51, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 29% over the past three years.Declared Dividend • May 04Dividend of €0.35 announcedShareholders will receive a dividend of €0.35. Ex-date: 5th May 2026 Payment date: 7th May 2026 Dividend yield will be 2.0%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. EPS is expected to grow by 8.8% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공지 • May 03Umicore Sa Announces Chief Financial Officer Changes, Effective August 1, 2026Umicore SA announced the appointment of Lily Liu as Chief Financial Officer effective August 1, 2026. Mrs. Liu succeeds current CFO Wannes Peferoen who will leave the Company after twenty years of dedicated service. Post handover on August 1st, Mr. Peferoen will serve in a special advisory capacity until February 28, 2027 to ensure a seamless transition. Mrs. Liu joins Umicore from Synthomer, a specialty chemicals company listed on the London Stock Exchange, where she serves as CFO since July 2022. Holding both British and Australian citizenship, she brings more than twenty years of financial leadership experience across the chemicals, manufacturing, and engineering industries. Before her time at Synthomer, Mrs. Liu was CFO at Essentra plc, and previously held CFO positions with Xaar plc and Smiths Detection. She is also a non-executive director and audit committee member at DCC plc.Reported Earnings • Mar 31Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024)Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.4b (up 30% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.2%. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.공지 • Mar 30Umicore SA, Annual General Meeting, Apr 30, 2026Umicore SA, Annual General Meeting, Apr 30, 2026, at 17:00 Romance Standard Time.Reported Earnings • Feb 21Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024)Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.4b (up 30% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to decline by 56% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.4%. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Dec 17Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 33% to €17.49. The fair value is estimated to be €14.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 37% per annum. Earnings are forecast to grow by 22% per annum over the same time period.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €14.44, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.09 per share.공지 • Oct 17+ 1 more updateUmicore SA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Umicore SA announced that they will report fiscal year 2025 final results on Mar 27, 2026Buy Or Sell Opportunity • Sep 25Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to €14.42. The fair value is estimated to be €12.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 41% per annum. Earnings are forecast to grow by 21% per annum over the same time period.공지 • Aug 22Umicore SA to Report Fiscal Year 2025 Results on Feb 20, 2026Umicore SA announced that they will report fiscal year 2025 results on Feb 20, 2026Reported Earnings • Aug 04First half 2025 earnings released: EPS: €0.57 (vs €6.12 loss in 1H 2024)First half 2025 results: EPS: €0.57 (up from €6.12 loss in 1H 2024). Revenue: €8.69b (up 17% from 1H 2024). Net income: €136.7m (up €1.61b from 1H 2024). Profit margin: 1.6% (up from net loss in 1H 2024). Revenue is expected to decline by 42% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.New Risk • Aug 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (213% cash payout ratio). Large one-off items impacting financial results.New Risk • Jun 24New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.8% average weekly change).Upcoming Dividend • Apr 21Upcoming dividend of €0.17 per shareEligible shareholders must have bought the stock before 28 April 2025. Payment date: 30 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 6.5%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (4.1%).New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.1% average weekly change).Reported Earnings • Mar 23Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023)Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.9%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.공지 • Mar 21Umicore Announces Supervisory Board ChangesUmicore at its ordinary and special shareholders’ meetings to be held on April 24, 2025 announced after serving 10 years on Umicore’s Supervisory Board, Mr. Mark Garrett announced that he will not seek to renew his mandate at the upcoming 2025 ordinary shareholders’ meeting. Mr. Laurent Raets, Groupe Bruxelles Lambert (GBL), also announced his intention to step down from the Supervisory Board, after having served 6 years on the Board.Declared Dividend • Feb 24Final dividend of €0.17 announcedShareholders will receive a dividend of €0.17. Ex-date: 28th April 2025 Payment date: 30th April 2025 Dividend yield will be 3.8%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (42% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time.공지 • Feb 17Umicore SA, Annual General Meeting, Apr 30, 2025Umicore SA, Annual General Meeting, Apr 30, 2025.Reported Earnings • Feb 15Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023)Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to decline by 38% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.9%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.공지 • Feb 15Umicore Sa Proposes Annual Dividend, Payable on April 30, 2025Umicore SA's Supervisory Board will propose a gross annual dividend of €0.50 per share for 2024 at the Annual General Meeting on 24 April 2025. This is a reduction from the €0.80 per share paid for 2023. Considering the interim dividend of €0.25 per share paid in August 2024, a gross amount of €0.25 per share will be paid on 30 April 2025, subject to shareholder approval. Based on the closing share price on 31 December 2024 of €9.96, the dividend yield amounts to approximately 5%.공지 • Feb 14Umicore SA to Report Fiscal Year 2024 Final Results on Mar 21, 2025Umicore SA announced that they will report fiscal year 2024 final results on Mar 21, 2025공지 • Feb 01Umicore SA to Report First Half, 2025 Results on Aug 01, 2025Umicore SA announced that they will report first half, 2025 results on Aug 01, 2025공지 • Dec 23+ 2 more updatesUmicore SA(ENXTBR:UMI) dropped from S&P EUROPE 350Umicore SA(ENXTBR:UMI) dropped from S&P EUROPE 350공지 • Sep 23Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD)Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD)Upcoming Dividend • Aug 12Upcoming dividend of €0.17 per shareEligible shareholders must have bought the stock before 19 August 2024. Payment date: 21 August 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (5.6%).Declared Dividend • Jul 31First half dividend of €0.17 announcedShareholders will receive a dividend of €0.17. Ex-date: 19th August 2024 Payment date: 21st August 2024 Dividend yield will be 4.4%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time.Reported Earnings • Jul 28First half 2024 earnings released: €6.12 loss per share (vs €0.93 profit in 1H 2023)First half 2024 results: €6.12 loss per share (down from €0.93 profit in 1H 2023). Revenue: €7.52b (down 25% from 1H 2023). Net loss: €1.47b (down €1.70b from profit in 1H 2023). Revenue is expected to decline by 43% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 4.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.New Risk • Jul 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 70% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making.Buy Or Sell Opportunity • Jul 28Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €13.13. The fair value is estimated to be €16.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company became loss making.공지 • Jul 26Umicore SA to Report Fiscal Year 2024 Results on Feb 14, 2025Umicore SA announced that they will report fiscal year 2024 results on Feb 14, 2025New Risk • Jun 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (122% cash payout ratio).Buy Or Sell Opportunity • Jun 10Now 21% overvaluedOver the last 90 days, the stock has fallen 20% to €16.82. The fair value is estimated to be €13.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 40% per annum. Earnings are forecast to grow by 0.6% per annum over the same time period.공지 • Feb 16Umicore SA to Report First Half, 2024 Results on Jul 26, 2024Umicore SA announced that they will report first half, 2024 results on Jul 26, 2024이익 및 매출 성장 예측XTRA:NVJP - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,929448299770712/31/20273,828392230709912/31/20263,718373383645912/31/202519,388385386711N/A9/30/202517,753257221590N/A6/30/202516,11512957470N/A3/31/202515,492-676172669N/A12/31/202414,869-1,480287869N/A9/30/202415,292-1,3953131,015N/A6/30/202415,715-1,3103401,160N/A3/31/202416,998-4632491,102N/A12/31/202318,2803851581,043N/A9/30/202320,4264352764N/A6/30/202322,571484-153486N/A3/31/202324,010527-5560N/A12/31/202225,449570143634N/A9/30/202224,863549307771N/A6/30/202224,278528470908N/A3/31/202224,1725736561,083N/A12/31/202124,0666198431,259N/A9/30/202123,7465297241,155N/A6/30/202123,4274406051,052N/A3/31/202122,072285352790N/A12/31/202020,71613199528N/A9/30/202020,29818050506N/A6/30/202019,8802301483N/A3/31/202018,687259-49481N/A12/31/201917,494288-99479N/A9/30/201916,223296N/A333N/A6/30/201914,953304N/A187N/A3/31/201914,339311N/A80N/A12/31/201813,726317N/A-27N/A9/30/201812,895291N/A53N/A6/30/201812,063265N/A133N/A3/31/201812,010240N/A143N/A12/31/201711,957215N/A153N/A9/30/201711,913204N/A211N/A6/30/201711,870194N/A268N/A3/31/201711,157187N/A326N/A12/31/201610,444181N/A385N/A9/30/20169,957175N/A384N/A6/30/20169,471168N/A382N/A3/31/20169,584161N/A324N/A12/31/20159,698153N/A265N/A9/30/20159,957175N/A263N/A6/30/20159,161170N/A253N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NVJP 의 연간 예상 수익 증가율(4.4%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: NVJP 의 연간 수익(4.4%)이 German 시장(16.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: NVJP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: NVJP 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -40.4%).고성장 매출: NVJP 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -40.4%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: NVJP의 자본 수익률은 3년 후 14.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/06 10:35종가2026/05/06 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Umicore SA는 32명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rupesh MadlaniBarclaysJames StewartBarclaysSebastian BrayBerenberg29명의 분석가 더 보기
공지 • May 06Umicore Announces Supervisory Board AppointmentsUmicore at its ordinary and extraordinary shareholders’ meeting held on April 30th 2026 approved the appointment of Anna Bertona and Benjamin Loh as new Supervisory Board members for a term of 3 years.
Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €19.51, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 29% over the past three years.
Declared Dividend • May 04Dividend of €0.35 announcedShareholders will receive a dividend of €0.35. Ex-date: 5th May 2026 Payment date: 7th May 2026 Dividend yield will be 2.0%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (31% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. EPS is expected to grow by 8.8% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공지 • May 03Umicore Sa Announces Chief Financial Officer Changes, Effective August 1, 2026Umicore SA announced the appointment of Lily Liu as Chief Financial Officer effective August 1, 2026. Mrs. Liu succeeds current CFO Wannes Peferoen who will leave the Company after twenty years of dedicated service. Post handover on August 1st, Mr. Peferoen will serve in a special advisory capacity until February 28, 2027 to ensure a seamless transition. Mrs. Liu joins Umicore from Synthomer, a specialty chemicals company listed on the London Stock Exchange, where she serves as CFO since July 2022. Holding both British and Australian citizenship, she brings more than twenty years of financial leadership experience across the chemicals, manufacturing, and engineering industries. Before her time at Synthomer, Mrs. Liu was CFO at Essentra plc, and previously held CFO positions with Xaar plc and Smiths Detection. She is also a non-executive director and audit committee member at DCC plc.
Reported Earnings • Mar 31Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024)Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.4b (up 30% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.2%. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
공지 • Mar 30Umicore SA, Annual General Meeting, Apr 30, 2026Umicore SA, Annual General Meeting, Apr 30, 2026, at 17:00 Romance Standard Time.
Reported Earnings • Feb 21Full year 2025 earnings released: EPS: €1.60 (vs €6.15 loss in FY 2024)Full year 2025 results: EPS: €1.60 (up from €6.15 loss in FY 2024). Revenue: €19.4b (up 30% from FY 2024). Net income: €384.5m (up €1.86b from FY 2024). Profit margin: 2.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is expected to decline by 56% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.4%. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Dec 17Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 33% to €17.49. The fair value is estimated to be €14.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 37% per annum. Earnings are forecast to grow by 22% per annum over the same time period.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €14.44, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.09 per share.
공지 • Oct 17+ 1 more updateUmicore SA to Report Fiscal Year 2025 Final Results on Mar 27, 2026Umicore SA announced that they will report fiscal year 2025 final results on Mar 27, 2026
Buy Or Sell Opportunity • Sep 25Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to €14.42. The fair value is estimated to be €12.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 41% per annum. Earnings are forecast to grow by 21% per annum over the same time period.
공지 • Aug 22Umicore SA to Report Fiscal Year 2025 Results on Feb 20, 2026Umicore SA announced that they will report fiscal year 2025 results on Feb 20, 2026
Reported Earnings • Aug 04First half 2025 earnings released: EPS: €0.57 (vs €6.12 loss in 1H 2024)First half 2025 results: EPS: €0.57 (up from €6.12 loss in 1H 2024). Revenue: €8.69b (up 17% from 1H 2024). Net income: €136.7m (up €1.61b from 1H 2024). Profit margin: 1.6% (up from net loss in 1H 2024). Revenue is expected to decline by 42% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
New Risk • Aug 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (213% cash payout ratio). Large one-off items impacting financial results.
New Risk • Jun 24New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.8% average weekly change).
Upcoming Dividend • Apr 21Upcoming dividend of €0.17 per shareEligible shareholders must have bought the stock before 28 April 2025. Payment date: 30 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 6.5%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (4.1%).
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.1% average weekly change).
Reported Earnings • Mar 23Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023)Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.9%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
공지 • Mar 21Umicore Announces Supervisory Board ChangesUmicore at its ordinary and special shareholders’ meetings to be held on April 24, 2025 announced after serving 10 years on Umicore’s Supervisory Board, Mr. Mark Garrett announced that he will not seek to renew his mandate at the upcoming 2025 ordinary shareholders’ meeting. Mr. Laurent Raets, Groupe Bruxelles Lambert (GBL), also announced his intention to step down from the Supervisory Board, after having served 6 years on the Board.
Declared Dividend • Feb 24Final dividend of €0.17 announcedShareholders will receive a dividend of €0.17. Ex-date: 28th April 2025 Payment date: 30th April 2025 Dividend yield will be 3.8%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (42% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time.
공지 • Feb 17Umicore SA, Annual General Meeting, Apr 30, 2025Umicore SA, Annual General Meeting, Apr 30, 2025.
Reported Earnings • Feb 15Full year 2024 earnings released: €6.15 loss per share (vs €1.60 profit in FY 2023)Full year 2024 results: €6.15 loss per share (down from €1.60 profit in FY 2023). Revenue: €14.9b (down 19% from FY 2023). Net loss: €1.48b (down 484% from profit in FY 2023). Revenue is expected to decline by 38% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.9%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
공지 • Feb 15Umicore Sa Proposes Annual Dividend, Payable on April 30, 2025Umicore SA's Supervisory Board will propose a gross annual dividend of €0.50 per share for 2024 at the Annual General Meeting on 24 April 2025. This is a reduction from the €0.80 per share paid for 2023. Considering the interim dividend of €0.25 per share paid in August 2024, a gross amount of €0.25 per share will be paid on 30 April 2025, subject to shareholder approval. Based on the closing share price on 31 December 2024 of €9.96, the dividend yield amounts to approximately 5%.
공지 • Feb 14Umicore SA to Report Fiscal Year 2024 Final Results on Mar 21, 2025Umicore SA announced that they will report fiscal year 2024 final results on Mar 21, 2025
공지 • Feb 01Umicore SA to Report First Half, 2025 Results on Aug 01, 2025Umicore SA announced that they will report first half, 2025 results on Aug 01, 2025
공지 • Dec 23+ 2 more updatesUmicore SA(ENXTBR:UMI) dropped from S&P EUROPE 350Umicore SA(ENXTBR:UMI) dropped from S&P EUROPE 350
공지 • Sep 23Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD)Umicore SA(ENXTBR:UMI) dropped from FTSE All-World Index (USD)
Upcoming Dividend • Aug 12Upcoming dividend of €0.17 per shareEligible shareholders must have bought the stock before 19 August 2024. Payment date: 21 August 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 7.0%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (5.6%).
Declared Dividend • Jul 31First half dividend of €0.17 announcedShareholders will receive a dividend of €0.17. Ex-date: 19th August 2024 Payment date: 21st August 2024 Dividend yield will be 4.4%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time.
Reported Earnings • Jul 28First half 2024 earnings released: €6.12 loss per share (vs €0.93 profit in 1H 2023)First half 2024 results: €6.12 loss per share (down from €0.93 profit in 1H 2023). Revenue: €7.52b (down 25% from 1H 2023). Net loss: €1.47b (down €1.70b from profit in 1H 2023). Revenue is expected to decline by 43% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 4.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
New Risk • Jul 28New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 70% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Paying a dividend despite being loss-making.
Buy Or Sell Opportunity • Jul 28Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €13.13. The fair value is estimated to be €16.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company became loss making.
공지 • Jul 26Umicore SA to Report Fiscal Year 2024 Results on Feb 14, 2025Umicore SA announced that they will report fiscal year 2024 results on Feb 14, 2025
New Risk • Jun 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (122% cash payout ratio).
Buy Or Sell Opportunity • Jun 10Now 21% overvaluedOver the last 90 days, the stock has fallen 20% to €16.82. The fair value is estimated to be €13.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 40% per annum. Earnings are forecast to grow by 0.6% per annum over the same time period.
공지 • Feb 16Umicore SA to Report First Half, 2024 Results on Jul 26, 2024Umicore SA announced that they will report first half, 2024 results on Jul 26, 2024